Dr. Jerome Kim, Director General of IVI (left), standing next to TriLink’s Chief Commercial Officer, Becky Buzzeo, after signing the 'Memorandum of Understanding to Support the Development of ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement ...

New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced ...

SAN DIEGO, Jan. 7, 2020 /PRNewswire/ -- TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United ...

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the ...

TriLink BioTechnologies, Inc. and Lucigen Corporation have announced that the two companies have signed a licensing agreement for the use of TriLink’s CleanAmp™ dNTPs in Lucigen’s new Taq98™ Hot Start ...

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has launched its newest ...

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was ...

Officinae Bio's AI-driven sequence optimization expands Maravai's family of brands, enabling rapid, cost-effective nucleic acid therapy development Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global ...

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...